NCT00847834View on ClinicalTrials.gov

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

PHASE4CompletedINTERVENTIONAL
Enrollment

968

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2004

Conditions
Hypertension
Interventions
DRUG

Irbesartan 150mg / Hydrochlorothiazide 12.5mg

Once a day

DRUG

Irbesartan 150mg

Once a day

Trial Locations (1)

Unknown

Sanofi aventis administrative office, Beijing

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00847834 - Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population | Biotech Hunter | Biotech Hunter